Philidor

"Fake news" strikes again — and this time spooks Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors. Shares fell 5 percent Wednesday afternoon following a Reuters report "announcing" the SEC’s investigation of Salix for possible securities law violations. However...

The culprit behind price gouging? In tweets sent out Thursday directed at President-elect Donald Trump, Citron Research targeted pharmacy benefit giant Express Scripts Holding Company (NASDAQ: ESRX), referring to the company as "the Philidor of the pharma industry," and setting a $45...

Pershing Square Holding, the hedge fund controlled by billionaire Bill Ackman, once more brought home a bad report card. Monthly portfolio update issued by the company for October showed that net performance of the fund was down 22.5 percent in the year-to-date period. This is despite the broader...

Wells Fargo reiterated its Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), saying the new Bloomberg report over potential accounting fraud charges on the company makes the stock further risky for investment. Bloomberg reported that U.S. authorities are investigating potential...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plummeted more than 12 percent Monday afternoon and hit a new 52-week low of $17.75 following a Bloomberg report that U.S. prosecutors are focusing on the company's ex-CEO and ex-CFO. Bloomberg reported shortly before Monday's market close...

One of the most incredible market stories of the last year has been the absolute implosion of Valeant Pharmaceuticals Intl Inc (NYSE: VRX). In the not too distant past, Valeant was one of the top performing stocks in the entire market, and certainly for its size. In mid-2012, shares were trading...

On the back of news from Valeant Pharmaceuticals Intl Inc (NYSE: VRX) regarding changes to its board of directors, former CFO Howard Schiller has defended his decision to not step down from the board. In a Monday press release, the company outlined upcoming changes, including the voluntary...

Amid a sinking stock price and a flurry of downgrades, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has released some progressive news In a press release, Valeant announced a search for a new CEO, Bill Ackman as a new member of the board and other internal matters such as the 10-K filing delay...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) started the week lower with a 10.7 percent decline in Monday's regular session and 7 percent decline after hours. The selloff was driven by several catalysts. Premarket Shares gained almost 2 percent in the premarket following...

Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares plunged nearly 9 percent in Monday's after-hours trading session following word the company may have to restate financial results, before recovering slightly. The potential restatement, according to sources, would come on the heels of a...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have appreciated 17.21 percent over the past three months, while declining 0.35 percent over the past month. Rodman & Renshaw’s Raghuram Selvaraju has initiated coverage of the company with a Buy rating and price target of $150...